Tom Steyer's portfolio
Multi-strategy global value and event-driven; long/short across equities, credit, and real estate.
What changed in Q2 2026
Compared with the previous 13F. Values are as reported at quarter end. How to read a 13F.
New positions
- SPYSPY$4.5B
- SOXXSOXX$83M
- Parabilis MedicinesPBLS$65M
- Novartis AG ADRNVS$57M
- Warby ParkerWRBY$25M
- Kailera Therapeutics, Inc. Common StockKLRA$24M
- BiogenBIIB$15M
- Taysha Gene TherapiesTSHA$15M
- Mobia Medical, Inc. Common StockMOBI$15M
- Alamar Biosciences, Inc. Common StockALMR$13M
Added to
- Electronic ArtsEA$1.6B
- BridgeBio PharmaBBIO$800M
- ExelixisEXEL$733M
- Thermo Fisher ScientificTMO$526M
- Roivant SciencesROIV$506M
- Boston ScientificBSX$449M
- Tango TherapeuticsTNGX$384M
- Beam TherapeuticsBEAM$351M
- GRAIL, LLCGRAL$284M
- ImmunovantIMVT$224M
Trimmed
- Revolution MedicinesRVMD$2.5B
- Liquidia TechnologiesLQDA$667M
- Amazon.comAMZN$628M
- NateraNTRA$602M
- UnitedHealth GroupUNH$528M
- AonAON$459M
- BroadcomAVGO$435M
- MicrosoftMSFT$415M
- KKR & Co.KKR$378M
- SynopsysSNPS$370M
Sold out
None this quarter.
Holdings
85 US-listed positions in the Q2 2026 13F, largest first (top 50 shown; all of them in Investingly).
| Stock | % of portfolio | Value | Shares | Last quarter |
|---|---|---|---|---|
| SPYSPY | 20.80% | $4.5B | 6,000,000 | New |
| Revolution MedicinesRVMD | 11.78% | $2.5B | 13,550,796 | Trimmed |
| Electronic ArtsEA | 7.54% | $1.6B | 7,919,500 | Added |
| BridgeBio PharmaBBIO | 3.71% | $800M | 10,743,063 | Added |
| Protagonist TherapeuticsPTGX | 3.61% | $778M | 6,348,906 | Held |
| ExelixisEXEL | 3.40% | $733M | 13,468,010 | Added |
| Liquidia TechnologiesLQDA | 3.10% | $667M | 8,365,038 | Trimmed |
| Amazon.comAMZN | 2.91% | $628M | 2,632,994 | Trimmed |
| Lantheus Hldgs | 2.88% | $619M | 5,583,479 | Held |
| NateraNTRA | 2.80% | $602M | 2,218,366 | Trimmed |
| UnitedHealth GroupUNH | 2.45% | $528M | 1,270,532 | Trimmed |
| Thermo Fisher ScientificTMO | 2.44% | $526M | 1,049,185 | Added |
| Roivant SciencesROIV | 2.35% | $506M | 14,309,000 | Added |
| AonAON | 2.13% | $459M | 1,382,562 | Trimmed |
| Boston ScientificBSX | 2.08% | $449M | 10,521,184 | Added |
| BroadcomAVGO | 2.02% | $435M | 1,151,800 | Trimmed |
| MicrosoftMSFT | 1.93% | $415M | 1,112,863 | Trimmed |
| Tango TherapeuticsTNGX | 1.78% | $384M | 12,277,000 | Added |
| KKR & Co.KKR | 1.75% | $378M | 4,118,300 | Trimmed |
| SynopsysSNPS | 1.72% | $370M | 829,600 | Trimmed |
| Beam TherapeuticsBEAM | 1.63% | $351M | 10,236,396 | Added |
| Crinetics Pharmaceuticals In | 1.56% | $336M | 8,989,098 | Held |
| GRAIL, LLCGRAL | 1.32% | $284M | 4,161,584 | Added |
| Westinghouse Air Brake TechnologiesWAB | 1.12% | $241M | 894,503 | Trimmed |
| ImmunovantIMVT | 1.04% | $224M | 5,805,000 | Added |
| Twist BioscienceTWST | 1.02% | $220M | 2,136,400 | Added |
| Agios PharmAGIO | 1.02% | $220M | 5,917,400 | Added |
| Aramark HoldingsARMK | 0.96% | $206M | 3,625,731 | Trimmed |
| BaiduBIDU | 0.64% | $138M | 1,203,785 | Added |
| Novo Nordisk A/SNVO | 0.58% | $126M | 2,619,000 | Added |
| Acadia Healthcare CompanyACHC | 0.58% | $125M | 4,220,800 | Added |
| BrightSpring Health Services, Inc. Common StockBTSG | 0.56% | $121M | 1,732,800 | Added |
| AstraZenecaAZN | 0.51% | $109M | 574,000 | Added |
| Johnson & JohnsonJNJ | 0.48% | $104M | 408,000 | Added |
| SOXXSOXX | 0.39% | $83M | 130,000 | New |
| Parabilis MedicinesPBLS | 0.30% | $65M | 2,368,200 | New |
| Novartis AG ADRNVS | 0.26% | $57M | 363,000 | New |
| Guardant HealthGH | 0.22% | $48M | 322,200 | Added |
| Avalo TherapeuticsAVTX | 0.21% | $46M | 2,498,000 | Added |
| JOYYJOYY | 0.21% | $46M | 699,200 | Added |
| Assembly BiosciencesASMB | 0.20% | $44M | 1,604,590 | Added |
| Enanta PharmaceuticalsENTA | 0.16% | $35M | 2,418,202 | Trimmed |
| Maze Therapeutics, Inc. Common StockMAZE | 0.15% | $33M | 1,107,814 | Added |
| CG Oncology, Inc. Common stockCGON | 0.13% | $28M | 400,000 | Trimmed |
| Merck & CompanyMRK | 0.12% | $26M | 199,000 | Trimmed |
| Warby ParkerWRBY | 0.12% | $25M | 828,000 | New |
| Perceptive Cap Solutions Cor | 0.11% | $24M | 2,250,000 | Held |
| Kailera Therapeutics, Inc. Common StockKLRA | 0.11% | $24M | 1,100,000 | New |
| Rio Tinto ADRRIO | 0.08% | $17M | 183,475 | Added |
| Axalta Coating Sys | 0.08% | $16M | 478,000 | Held |
By sector
Share of the reported value.
Reported value over time
Total 13F value at each quarter end.
Questions
What stocks does Tom Steyer own?
In the Q2 2026 13F, Farallon Capital Management LLC reported 85 US stock positions worth $21.5B. The largest: SPY (SPY) 20.8%, Revolution Medicines (RVMD) 11.8%, Electronic Arts (EA) 7.5%, BridgeBio Pharma (BBIO) 3.7%, Protagonist Therapeutics (PTGX) 3.6%.
What did Tom Steyer buy last quarter?
In Q2 2026: new position in SPY (SPY); new position in SOXX (SOXX); new position in Parabilis Medicines (PBLS); added to Electronic Arts (EA); added to BridgeBio Pharma (BBIO); added to Exelixis (EXEL).
When is Tom Steyer's next 13F?
13F filings are due 45 days after each quarter ends. The Q3 2026 filing is due by November 14, 2026.
More investors
13F filings list US-listed long positions (and some options) held at quarter end. They leave out short positions, cash,
bonds and non-US holdings, and arrive up to 45 days after the quarter ends, so the investor may have traded since. Information only, not investment advice.
Photo: Gage Skidmore from Surprise, AZ, United States of America (credits).